Annexon Inc (ANNX)
$7.63
+0.01
(+0.13%)▲
Performance
- $7.56$7.75$7.63
0.98%
Downside
Day's Volatility :2.45%
Upside
1.48%
- $1.67$8.40$7.63
78.11%
Downside
52 Weeks Volatility :80.12%
Upside
9.17%
Returns
| Period | Annexon Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 29.81% | 1.8% | 0.0% |
6 Months | 66.19% | 10.7% | 0.0% |
1 Year | 330.51% | 17.0% | 0.0% |
3 Years | -63.28% | 19.8% | -21.9% |
Highlights
Market Capitalization | 787.1M |
Book Value | $3.42 |
Earnings Per Share (EPS) | -1.21 |
Wall Street Target Price | 16.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -24.83% |
Return On Equity TTM | -42.2% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -124.8M |
Diluted Eps TTM | -1.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.98 |
EPS Estimate Next Year | -1.14 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.26 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 114.94%
Technicals Summary
Sell
Neutral
Buy
Annexon Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Annexon Inc | 9.01% | 66.19% | 330.51% | -63.28% | -64.12% |
 Regeneron Pharmaceuticals, Inc. | -12.1% | 11.85% | 20.45% | 85.46% | 234.24% |
 Novo Nordisk A/s | -10.58% | -5.22% | 16.68% | 128.23% | 348.1% |
 Alnylam Pharmaceuticals, Inc. | 9.51% | 106.82% | 81.08% | 47.4% | 267.06% |
 Vertex Pharmaceuticals Incorporated | 1.24% | 23.95% | 30.46% | 169.5% | 174.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Annexon Inc | NA | NA | NA | -0.98 | -0.42 | -0.25 | NA | 3.42 |
Regeneron Pharmaceuticals, Inc. | 26.93 | 26.93 | 1.38 | 44.91 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.94 | 39.94 | 1.84 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Annexon Inc | Buy | $787.1M | -64.12% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $112.1B | 234.24% | 26.93 | 32.04% |
Novo Nordisk A/s | Buy | $522.1B | 348.1% | 39.94 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.9B | 267.06% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.0B | 174.17% | 32.84 | -4.74% |
Insights on Annexon Inc
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.1% return, outperforming this stock by 109.5%
Institutional Holdings
Bain Capital Life Sciences Investors, LLC
8.00%FMR Inc
7.86%SATTER MANAGEMENT CO., L.P.
7.01%Bvf Inc
6.63%Logos Global Management LP
6.25%BlackRock Inc
6.23%
Company Information
our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).
Organization | Annexon Inc |
Employees | 71 |
CEO | Mr. Douglas Love Esq., J.D. |
Industry | Health Technology |
